| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lenses, Intraocular | 126 | 2024 | 403 | 19.380 |
Why?
|
| Astigmatism | 70 | 2025 | 185 | 16.460 |
Why?
|
| Cornea | 128 | 2025 | 685 | 16.290 |
Why?
|
| Refraction, Ocular | 89 | 2025 | 316 | 12.590 |
Why?
|
| Phacoemulsification | 66 | 2024 | 243 | 12.090 |
Why?
|
| Lens Implantation, Intraocular | 83 | 2024 | 349 | 10.900 |
Why?
|
| Optics and Photonics | 38 | 2024 | 143 | 8.170 |
Why?
|
| Myopia | 48 | 2024 | 194 | 7.630 |
Why?
|
| Cataract Extraction | 61 | 2025 | 221 | 7.450 |
Why?
|
| Keratomileusis, Laser In Situ | 39 | 2020 | 149 | 6.880 |
Why?
|
| Corneal Topography | 61 | 2025 | 204 | 6.580 |
Why?
|
| Visual Acuity | 101 | 2025 | 869 | 6.130 |
Why?
|
| Refractive Surgical Procedures | 26 | 2025 | 77 | 5.500 |
Why?
|
| Hyperopia | 30 | 2020 | 83 | 5.490 |
Why?
|
| Biometry | 34 | 2024 | 143 | 5.490 |
Why?
|
| Cataract | 35 | 2024 | 230 | 5.310 |
Why?
|
| Photorefractive Keratectomy | 30 | 2020 | 81 | 5.260 |
Why?
|
| Refractive Errors | 27 | 2022 | 86 | 4.960 |
Why?
|
| Corneal Diseases | 17 | 2023 | 107 | 3.960 |
Why?
|
| Pseudophakia | 15 | 2024 | 75 | 3.260 |
Why?
|
| Tomography, Optical Coherence | 15 | 2021 | 586 | 2.960 |
Why?
|
| Axial Length, Eye | 17 | 2024 | 49 | 2.920 |
Why?
|
| Keratoconus | 10 | 2025 | 73 | 2.780 |
Why?
|
| Corneal Stroma | 12 | 2022 | 102 | 2.590 |
Why?
|
| Lasers, Excimer | 28 | 2020 | 101 | 2.520 |
Why?
|
| Corneal Wavefront Aberration | 7 | 2024 | 20 | 2.400 |
Why?
|
| Corneal Surgery, Laser | 6 | 2020 | 22 | 2.350 |
Why?
|
| Ophthalmology | 20 | 2017 | 217 | 2.270 |
Why?
|
| Humans | 308 | 2025 | 133950 | 1.900 |
Why?
|
| Keratotomy, Radial | 12 | 2022 | 33 | 1.870 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 13 | 2015 | 105 | 1.810 |
Why?
|
| Laser Therapy | 18 | 2018 | 252 | 1.720 |
Why?
|
| Reproducibility of Results | 35 | 2024 | 3056 | 1.600 |
Why?
|
| Image Processing, Computer-Assisted | 14 | 2016 | 621 | 1.480 |
Why?
|
| Epithelium, Corneal | 5 | 2019 | 176 | 1.460 |
Why?
|
| Middle Aged | 112 | 2024 | 29411 | 1.450 |
Why?
|
| Aged | 93 | 2024 | 21740 | 1.420 |
Why?
|
| Retrospective Studies | 77 | 2024 | 17496 | 1.400 |
Why?
|
| Pupil | 7 | 2023 | 74 | 1.390 |
Why?
|
| Surgical Flaps | 13 | 2018 | 212 | 1.350 |
Why?
|
| Models, Theoretical | 6 | 2018 | 397 | 1.310 |
Why?
|
| Surgeons | 4 | 2023 | 285 | 1.310 |
Why?
|
| Postoperative Complications | 36 | 2018 | 3227 | 1.280 |
Why?
|
| Prosthesis Implantation | 5 | 2018 | 149 | 1.280 |
Why?
|
| Presbyopia | 4 | 2018 | 31 | 1.250 |
Why?
|
| Prostheses and Implants | 6 | 2018 | 164 | 1.200 |
Why?
|
| Lens Capsule, Crystalline | 12 | 2014 | 50 | 1.160 |
Why?
|
| Prospective Studies | 44 | 2024 | 6662 | 1.130 |
Why?
|
| Lens, Crystalline | 10 | 2018 | 144 | 1.040 |
Why?
|
| Male | 115 | 2024 | 65909 | 1.020 |
Why?
|
| Depth Perception | 5 | 2024 | 23 | 1.010 |
Why?
|
| Adult | 87 | 2024 | 31958 | 1.010 |
Why?
|
| Vision Disorders | 8 | 2015 | 238 | 1.000 |
Why?
|
| Aged, 80 and over | 42 | 2024 | 7213 | 0.970 |
Why?
|
| Endothelium, Corneal | 7 | 2012 | 45 | 0.950 |
Why?
|
| Corneal Transplantation | 10 | 2011 | 50 | 0.940 |
Why?
|
| Fourier Analysis | 6 | 2013 | 61 | 0.910 |
Why?
|
| Aberrometry | 1 | 2024 | 12 | 0.910 |
Why?
|
| Female | 107 | 2024 | 71696 | 0.900 |
Why?
|
| Corneal Pachymetry | 4 | 2024 | 27 | 0.890 |
Why?
|
| Prosthesis Design | 16 | 2024 | 711 | 0.870 |
Why?
|
| Laser Coagulation | 7 | 1998 | 132 | 0.850 |
Why?
|
| Iris | 7 | 2022 | 65 | 0.850 |
Why?
|
| Corneal Neovascularization | 1 | 2023 | 13 | 0.840 |
Why?
|
| Algorithms | 11 | 2024 | 1736 | 0.830 |
Why?
|
| Anterior Chamber | 11 | 2018 | 58 | 0.830 |
Why?
|
| Burns, Chemical | 1 | 2023 | 31 | 0.820 |
Why?
|
| Microsurgery | 3 | 2014 | 72 | 0.820 |
Why?
|
| Suture Techniques | 11 | 2017 | 201 | 0.800 |
Why?
|
| Multifocal Intraocular Lenses | 2 | 2020 | 14 | 0.780 |
Why?
|
| Surgical Wound Dehiscence | 3 | 2012 | 51 | 0.720 |
Why?
|
| Publishing | 4 | 2011 | 118 | 0.720 |
Why?
|
| Wound Healing | 7 | 2018 | 495 | 0.710 |
Why?
|
| Consensus | 1 | 2025 | 740 | 0.710 |
Why?
|
| Eye | 5 | 2024 | 246 | 0.700 |
Why?
|
| Aging | 7 | 2015 | 1298 | 0.690 |
Why?
|
| Endophthalmitis | 4 | 2018 | 78 | 0.690 |
Why?
|
| Light | 5 | 2018 | 187 | 0.660 |
Why?
|
| Ultraviolet Rays | 3 | 2020 | 215 | 0.610 |
Why?
|
| Artificial Lens Implant Migration | 1 | 2018 | 9 | 0.610 |
Why?
|
| Postoperative Period | 8 | 2018 | 353 | 0.600 |
Why?
|
| Anterior Eye Segment | 3 | 2015 | 31 | 0.590 |
Why?
|
| Corneal Dystrophies, Hereditary | 2 | 2015 | 12 | 0.590 |
Why?
|
| Intraoperative Complications | 4 | 2008 | 175 | 0.590 |
Why?
|
| Keratoplasty, Penetrating | 7 | 2021 | 55 | 0.590 |
Why?
|
| Follow-Up Studies | 31 | 2016 | 5510 | 0.560 |
Why?
|
| Accommodation, Ocular | 4 | 2012 | 17 | 0.560 |
Why?
|
| Sclera | 8 | 2014 | 58 | 0.560 |
Why?
|
| Eye Infections, Bacterial | 1 | 2018 | 92 | 0.560 |
Why?
|
| Contact Lenses | 4 | 1999 | 45 | 0.540 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 128 | 0.540 |
Why?
|
| Anisometropia | 3 | 2005 | 12 | 0.530 |
Why?
|
| Lasers | 4 | 2024 | 118 | 0.520 |
Why?
|
| Contrast Sensitivity | 11 | 2017 | 62 | 0.510 |
Why?
|
| Emmetropia | 1 | 2016 | 6 | 0.510 |
Why?
|
| Descemet Membrane | 3 | 2012 | 16 | 0.500 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2016 | 29 | 0.500 |
Why?
|
| Models, Statistical | 3 | 2010 | 505 | 0.490 |
Why?
|
| Data Collection | 4 | 2005 | 397 | 0.490 |
Why?
|
| ROC Curve | 4 | 2025 | 616 | 0.480 |
Why?
|
| Corneal Opacity | 1 | 2015 | 25 | 0.470 |
Why?
|
| Serial Publications | 2 | 2015 | 4 | 0.460 |
Why?
|
| Biomedical Technology | 1 | 2015 | 37 | 0.450 |
Why?
|
| Patient Satisfaction | 10 | 2018 | 506 | 0.450 |
Why?
|
| Peer Review, Research | 2 | 2015 | 49 | 0.440 |
Why?
|
| Prosthesis Failure | 3 | 2012 | 166 | 0.440 |
Why?
|
| Hair Removal | 1 | 2013 | 8 | 0.430 |
Why?
|
| Microscopy, Electron, Scanning | 6 | 2012 | 153 | 0.430 |
Why?
|
| Periodicals as Topic | 3 | 2018 | 206 | 0.420 |
Why?
|
| Pupil Disorders | 2 | 2008 | 20 | 0.420 |
Why?
|
| Treatment Outcome | 28 | 2020 | 13011 | 0.410 |
Why?
|
| Biomedical Research | 3 | 2010 | 556 | 0.410 |
Why?
|
| Corneal Endothelial Cell Loss | 1 | 2012 | 9 | 0.400 |
Why?
|
| Young Adult | 15 | 2024 | 9888 | 0.380 |
Why?
|
| Torsion Abnormality | 2 | 2010 | 37 | 0.380 |
Why?
|
| Safety | 11 | 2004 | 224 | 0.380 |
Why?
|
| Amblyopia | 3 | 2005 | 32 | 0.360 |
Why?
|
| Anesthesia, Local | 2 | 2005 | 45 | 0.350 |
Why?
|
| Limbus Corneae | 3 | 2019 | 34 | 0.340 |
Why?
|
| Internship and Residency | 6 | 2017 | 1250 | 0.340 |
Why?
|
| Anesthetics, Local | 2 | 2005 | 96 | 0.330 |
Why?
|
| Mitomycin | 1 | 2009 | 53 | 0.310 |
Why?
|
| Vision Tests | 6 | 2023 | 36 | 0.310 |
Why?
|
| Terminology as Topic | 4 | 2018 | 237 | 0.310 |
Why?
|
| Prediabetic State | 1 | 2009 | 63 | 0.300 |
Why?
|
| Intraocular Pressure | 7 | 2019 | 151 | 0.280 |
Why?
|
| Blood Glucose | 2 | 2009 | 1190 | 0.280 |
Why?
|
| Diabetes, Gestational | 1 | 2009 | 115 | 0.270 |
Why?
|
| Iris Diseases | 1 | 2007 | 15 | 0.270 |
Why?
|
| Biocompatible Materials | 4 | 2005 | 135 | 0.270 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2007 | 19 | 0.270 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2007 | 39 | 0.270 |
Why?
|
| Data Display | 3 | 2011 | 15 | 0.270 |
Why?
|
| Methylmethacrylates | 5 | 1996 | 13 | 0.270 |
Why?
|
| Guidelines as Topic | 2 | 1998 | 201 | 0.270 |
Why?
|
| Lens Diseases | 2 | 2005 | 7 | 0.270 |
Why?
|
| Lidocaine | 2 | 2005 | 50 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2519 | 0.260 |
Why?
|
| Ethics, Medical | 3 | 2005 | 403 | 0.260 |
Why?
|
| Silicone Elastomers | 3 | 1998 | 35 | 0.260 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 566 | 0.250 |
Why?
|
| Scientific Misconduct | 1 | 2005 | 7 | 0.250 |
Why?
|
| Ocular Physiological Phenomena | 1 | 2005 | 6 | 0.240 |
Why?
|
| Cell Count | 4 | 2012 | 254 | 0.240 |
Why?
|
| Conflict of Interest | 2 | 2003 | 69 | 0.240 |
Why?
|
| Procaine | 1 | 2005 | 7 | 0.240 |
Why?
|
| Artificial Intelligence | 3 | 2024 | 297 | 0.240 |
Why?
|
| Journal Impact Factor | 2 | 2015 | 28 | 0.240 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2005 | 14 | 0.240 |
Why?
|
| Societies, Medical | 3 | 2010 | 777 | 0.240 |
Why?
|
| Sulfonamides | 1 | 2007 | 286 | 0.230 |
Why?
|
| Foreign-Body Migration | 1 | 2005 | 72 | 0.230 |
Why?
|
| Acrylic Resins | 1 | 2005 | 26 | 0.230 |
Why?
|
| Ophthalmic Solutions | 6 | 2000 | 94 | 0.230 |
Why?
|
| Vision, Binocular | 3 | 2024 | 48 | 0.230 |
Why?
|
| Education, Medical, Continuing | 2 | 2003 | 145 | 0.220 |
Why?
|
| Truth Disclosure | 1 | 2005 | 105 | 0.220 |
Why?
|
| Data Interpretation, Statistical | 1 | 2025 | 240 | 0.220 |
Why?
|
| Preoperative Period | 2 | 2024 | 96 | 0.220 |
Why?
|
| Research Personnel | 1 | 2005 | 135 | 0.220 |
Why?
|
| Nomograms | 2 | 2016 | 40 | 0.220 |
Why?
|
| Medicare | 1 | 2007 | 465 | 0.220 |
Why?
|
| Drug Hypersensitivity | 1 | 2005 | 101 | 0.220 |
Why?
|
| Probability | 1 | 2004 | 335 | 0.220 |
Why?
|
| Photography | 4 | 2015 | 101 | 0.210 |
Why?
|
| Football | 1 | 2003 | 36 | 0.210 |
Why?
|
| Surveys and Questionnaires | 7 | 2018 | 3993 | 0.200 |
Why?
|
| Drug Industry | 1 | 2003 | 48 | 0.200 |
Why?
|
| Eye Injuries | 1 | 2003 | 52 | 0.200 |
Why?
|
| Macular Degeneration | 1 | 2004 | 128 | 0.190 |
Why?
|
| Informed Consent | 1 | 2005 | 345 | 0.190 |
Why?
|
| Glare | 3 | 2018 | 16 | 0.190 |
Why?
|
| Prednisolone | 2 | 2000 | 80 | 0.190 |
Why?
|
| Neovascularization, Pathologic | 1 | 2023 | 263 | 0.190 |
Why?
|
| Peer Review | 1 | 2001 | 41 | 0.180 |
Why?
|
| Polymethyl Methacrylate | 3 | 1999 | 22 | 0.180 |
Why?
|
| Practice Patterns, Physicians' | 2 | 1999 | 766 | 0.180 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2021 | 50 | 0.180 |
Why?
|
| Machine Learning | 1 | 2024 | 334 | 0.180 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 935 | 0.170 |
Why?
|
| Research | 1 | 2002 | 272 | 0.170 |
Why?
|
| Respiratory Protective Devices | 1 | 2020 | 8 | 0.170 |
Why?
|
| Decontamination | 1 | 2020 | 13 | 0.170 |
Why?
|
| Interferometry | 2 | 2017 | 28 | 0.170 |
Why?
|
| Prodrugs | 1 | 2000 | 63 | 0.170 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2000 | 49 | 0.170 |
Why?
|
| Reoperation | 5 | 2009 | 866 | 0.160 |
Why?
|
| Equipment Contamination | 1 | 2020 | 40 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2022 | 158 | 0.160 |
Why?
|
| United States | 11 | 2022 | 11689 | 0.160 |
Why?
|
| Vitrectomy | 5 | 1997 | 112 | 0.160 |
Why?
|
| Keratitis | 1 | 2000 | 116 | 0.160 |
Why?
|
| Pterygium | 1 | 1999 | 5 | 0.160 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2019 | 10 | 0.160 |
Why?
|
| Clinical Competence | 4 | 2017 | 1066 | 0.160 |
Why?
|
| Materials Testing | 1 | 1999 | 80 | 0.160 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2019 | 39 | 0.160 |
Why?
|
| Predictive Value of Tests | 4 | 2013 | 2295 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 319 | 0.150 |
Why?
|
| Eye Neoplasms | 1 | 1999 | 53 | 0.150 |
Why?
|
| Case-Control Studies | 4 | 2013 | 3644 | 0.150 |
Why?
|
| Dermoid Cyst | 1 | 1999 | 34 | 0.150 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 1999 | 90 | 0.150 |
Why?
|
| Debridement | 1 | 2018 | 94 | 0.150 |
Why?
|
| Curriculum | 3 | 1998 | 775 | 0.150 |
Why?
|
| Iatrogenic Disease | 1 | 1999 | 136 | 0.150 |
Why?
|
| Datasets as Topic | 1 | 2018 | 104 | 0.150 |
Why?
|
| Aqueous Humor | 2 | 2015 | 28 | 0.140 |
Why?
|
| Blinking | 1 | 2018 | 27 | 0.140 |
Why?
|
| Adolescent | 13 | 2024 | 20544 | 0.140 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 1996 | 14 | 0.130 |
Why?
|
| Mathematics | 4 | 2016 | 97 | 0.130 |
Why?
|
| Edema | 3 | 1989 | 142 | 0.130 |
Why?
|
| Iridocyclitis | 1 | 2016 | 3 | 0.130 |
Why?
|
| Methacrylates | 1 | 1996 | 19 | 0.130 |
Why?
|
| Animals | 8 | 2023 | 36387 | 0.130 |
Why?
|
| Ophthalmoscopy | 1 | 2016 | 30 | 0.120 |
Why?
|
| Video Recording | 1 | 1997 | 204 | 0.120 |
Why?
|
| Hyaluronic Acid | 2 | 1996 | 116 | 0.120 |
Why?
|
| Silicones | 1 | 1995 | 36 | 0.120 |
Why?
|
| Bupivacaine | 1 | 1995 | 29 | 0.120 |
Why?
|
| Optical Imaging | 1 | 2016 | 74 | 0.120 |
Why?
|
| Dinoprostone | 1 | 2015 | 82 | 0.120 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 166 | 0.120 |
Why?
|
| Color | 2 | 1992 | 34 | 0.120 |
Why?
|
| Pilot Projects | 4 | 2005 | 1485 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 4778 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2016 | 245 | 0.110 |
Why?
|
| Ectopia Lentis | 1 | 2014 | 12 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 388 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 399 | 0.110 |
Why?
|
| Time Factors | 6 | 2016 | 6587 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2016 | 832 | 0.110 |
Why?
|
| Child | 14 | 2014 | 25766 | 0.110 |
Why?
|
| Vision, Ocular | 3 | 2023 | 139 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2003 | 1335 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2015 | 450 | 0.110 |
Why?
|
| Child, Preschool | 11 | 2014 | 14820 | 0.100 |
Why?
|
| Chondroitin | 1 | 1993 | 3 | 0.100 |
Why?
|
| Postoperative Care | 3 | 2002 | 310 | 0.100 |
Why?
|
| Stents | 1 | 2019 | 876 | 0.100 |
Why?
|
| Retinoscopy | 1 | 2012 | 10 | 0.100 |
Why?
|
| Cause of Death | 1 | 2015 | 504 | 0.100 |
Why?
|
| Observer Variation | 2 | 2010 | 312 | 0.100 |
Why?
|
| Aphakia, Postcataract | 2 | 2017 | 22 | 0.100 |
Why?
|
| Preoperative Care | 3 | 2002 | 372 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1195 | 0.100 |
Why?
|
| Rupture | 1 | 2012 | 34 | 0.100 |
Why?
|
| Rabbits | 3 | 1999 | 736 | 0.100 |
Why?
|
| Nylons | 1 | 2012 | 13 | 0.100 |
Why?
|
| Ciliary Body | 2 | 1989 | 32 | 0.090 |
Why?
|
| Tissue Adhesions | 1 | 2012 | 31 | 0.090 |
Why?
|
| Eyelid Diseases | 1 | 1992 | 75 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 561 | 0.090 |
Why?
|
| Eye Color | 2 | 2007 | 7 | 0.090 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2002 | 35 | 0.090 |
Why?
|
| Pathology | 1 | 2011 | 43 | 0.090 |
Why?
|
| Sutures | 1 | 2012 | 67 | 0.090 |
Why?
|
| Reflex, Pupillary | 1 | 1991 | 16 | 0.090 |
Why?
|
| Amyloidosis | 1 | 1992 | 73 | 0.090 |
Why?
|
| Publications | 1 | 2011 | 37 | 0.090 |
Why?
|
| Online Systems | 1 | 2010 | 17 | 0.090 |
Why?
|
| Research Report | 1 | 2011 | 79 | 0.080 |
Why?
|
| Light Coagulation | 1 | 1990 | 24 | 0.080 |
Why?
|
| Myotonic Dystrophy | 1 | 1992 | 150 | 0.080 |
Why?
|
| Documentation | 1 | 2011 | 123 | 0.080 |
Why?
|
| Georgia | 1 | 2009 | 38 | 0.080 |
Why?
|
| Activities of Daily Living | 2 | 2004 | 430 | 0.080 |
Why?
|
| Brain Damage, Chronic | 1 | 1989 | 31 | 0.080 |
Why?
|
| History, 21st Century | 2 | 2011 | 279 | 0.080 |
Why?
|
| Dominance, Cerebral | 1 | 1989 | 56 | 0.080 |
Why?
|
| Eye Diseases | 1 | 2010 | 138 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 165 | 0.080 |
Why?
|
| History, 20th Century | 2 | 2011 | 398 | 0.070 |
Why?
|
| Equipment Design | 2 | 2003 | 613 | 0.070 |
Why?
|
| Glucose Intolerance | 1 | 2009 | 83 | 0.070 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 224 | 0.070 |
Why?
|
| Microscopy | 1 | 1989 | 123 | 0.070 |
Why?
|
| Intelligence | 1 | 1989 | 108 | 0.070 |
Why?
|
| Biosensing Techniques | 1 | 1988 | 68 | 0.070 |
Why?
|
| Insurance Claim Reporting | 1 | 2007 | 8 | 0.070 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 1988 | 124 | 0.070 |
Why?
|
| Acrylates | 1 | 2007 | 12 | 0.070 |
Why?
|
| Cadaver | 2 | 1998 | 141 | 0.070 |
Why?
|
| Body Weights and Measures | 2 | 2004 | 45 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2015 | 886 | 0.070 |
Why?
|
| Atropine | 1 | 2007 | 31 | 0.070 |
Why?
|
| Surgical Instruments | 2 | 1998 | 58 | 0.070 |
Why?
|
| Vision Disparity | 1 | 2007 | 2 | 0.070 |
Why?
|
| China | 2 | 2019 | 295 | 0.070 |
Why?
|
| Ocular Hypertension | 2 | 1997 | 26 | 0.070 |
Why?
|
| Retinal Diseases | 1 | 1989 | 181 | 0.070 |
Why?
|
| Retinal Detachment | 3 | 2001 | 87 | 0.070 |
Why?
|
| Patient Selection | 2 | 2002 | 734 | 0.070 |
Why?
|
| Retinoscopes | 1 | 2006 | 5 | 0.070 |
Why?
|
| Incidence | 4 | 2007 | 3402 | 0.070 |
Why?
|
| Keratan Sulfate | 2 | 1996 | 7 | 0.060 |
Why?
|
| Child Development | 1 | 1989 | 287 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2015 | 1128 | 0.060 |
Why?
|
| Mice | 1 | 2023 | 18911 | 0.060 |
Why?
|
| Competitive Behavior | 1 | 2005 | 11 | 0.060 |
Why?
|
| Bibliometrics | 1 | 2006 | 38 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 1314 | 0.060 |
Why?
|
| Vision, Low | 2 | 2017 | 15 | 0.060 |
Why?
|
| Cell Death | 1 | 2006 | 251 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 2164 | 0.060 |
Why?
|
| Injections | 2 | 1998 | 159 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 1988 | 325 | 0.060 |
Why?
|
| Skin Tests | 1 | 2005 | 83 | 0.060 |
Why?
|
| Collagen | 2 | 1996 | 334 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2007 | 701 | 0.060 |
Why?
|
| Academies and Institutes | 2 | 2002 | 88 | 0.060 |
Why?
|
| Altitude Sickness | 1 | 1984 | 3 | 0.060 |
Why?
|
| Syndrome | 1 | 2007 | 1165 | 0.050 |
Why?
|
| Visual Fields | 2 | 2004 | 151 | 0.050 |
Why?
|
| Anthropometry | 2 | 1996 | 202 | 0.050 |
Why?
|
| Practice Management, Medical | 1 | 2003 | 11 | 0.050 |
Why?
|
| Surface Properties | 2 | 1995 | 95 | 0.050 |
Why?
|
| Texas | 3 | 1998 | 3688 | 0.050 |
Why?
|
| Electrocoagulation | 2 | 1997 | 35 | 0.050 |
Why?
|
| Mass Screening | 1 | 2009 | 835 | 0.050 |
Why?
|
| Quality of Life | 2 | 2022 | 2143 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 138 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 2003 | 121 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2005 | 478 | 0.050 |
Why?
|
| Career Mobility | 1 | 2002 | 54 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2023 | 261 | 0.050 |
Why?
|
| Scattering, Radiation | 2 | 1993 | 57 | 0.050 |
Why?
|
| Photophobia | 1 | 2022 | 9 | 0.050 |
Why?
|
| Dry Eye Syndromes | 1 | 2006 | 281 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 1532 | 0.050 |
Why?
|
| Hypoxia | 1 | 1984 | 263 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2003 | 941 | 0.050 |
Why?
|
| Blepharoptosis | 2 | 1992 | 68 | 0.040 |
Why?
|
| Infant | 5 | 2004 | 13176 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2002 | 1153 | 0.040 |
Why?
|
| Prognosis | 3 | 2000 | 5080 | 0.040 |
Why?
|
| Equipment Reuse | 1 | 2020 | 7 | 0.040 |
Why?
|
| Optic Disk | 1 | 2000 | 50 | 0.040 |
Why?
|
| Health Services Research | 1 | 2001 | 190 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2003 | 278 | 0.040 |
Why?
|
| Gonioscopy | 1 | 2019 | 10 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2021 | 284 | 0.040 |
Why?
|
| Tonometry, Ocular | 1 | 2019 | 32 | 0.040 |
Why?
|
| Automobile Driving | 1 | 1999 | 34 | 0.040 |
Why?
|
| Twins, Dizygotic | 1 | 1999 | 47 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 1998 | 9 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 1999 | 97 | 0.040 |
Why?
|
| Health Status | 1 | 2001 | 411 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2019 | 249 | 0.040 |
Why?
|
| Twins, Monozygotic | 1 | 1999 | 129 | 0.040 |
Why?
|
| Optical Phenomena | 1 | 2018 | 13 | 0.040 |
Why?
|
| Disease Progression | 1 | 2024 | 2243 | 0.040 |
Why?
|
| Astronauts | 1 | 1999 | 76 | 0.040 |
Why?
|
| Therapeutic Irrigation | 1 | 1998 | 43 | 0.040 |
Why?
|
| Glaucoma | 2 | 1997 | 96 | 0.040 |
Why?
|
| Levobunolol | 1 | 1997 | 2 | 0.040 |
Why?
|
| Timolol | 1 | 1997 | 9 | 0.040 |
Why?
|
| Lens Nucleus, Crystalline | 2 | 1995 | 4 | 0.030 |
Why?
|
| Trabeculectomy | 1 | 1997 | 18 | 0.030 |
Why?
|
| Naphazoline | 1 | 1997 | 2 | 0.030 |
Why?
|
| Nasal Decongestants | 1 | 1997 | 4 | 0.030 |
Why?
|
| Phenylephrine | 1 | 1997 | 39 | 0.030 |
Why?
|
| Conjunctivitis | 1 | 1997 | 22 | 0.030 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 1997 | 83 | 0.030 |
Why?
|
| Holmium | 1 | 1996 | 10 | 0.030 |
Why?
|
| Heparin | 1 | 1998 | 225 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 309 | 0.030 |
Why?
|
| Pregnancy | 1 | 2009 | 7524 | 0.030 |
Why?
|
| Professional Practice | 1 | 1996 | 43 | 0.030 |
Why?
|
| Integrin beta4 | 1 | 1996 | 3 | 0.030 |
Why?
|
| Photomicrography | 1 | 1996 | 12 | 0.030 |
Why?
|
| Procollagen | 1 | 1996 | 18 | 0.030 |
Why?
|
| Propoxycaine | 1 | 1995 | 3 | 0.030 |
Why?
|
| Reference Standards | 1 | 2017 | 245 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 1999 | 463 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 104 | 0.030 |
Why?
|
| Device Approval | 1 | 1995 | 12 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 374 | 0.030 |
Why?
|
| Tomography | 1 | 2015 | 41 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 187 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1997 | 252 | 0.030 |
Why?
|
| Anesthetics, Intravenous | 1 | 1995 | 47 | 0.030 |
Why?
|
| Space Flight | 1 | 1999 | 170 | 0.030 |
Why?
|
| Integrins | 1 | 1996 | 103 | 0.030 |
Why?
|
| Imidazoles | 1 | 1997 | 217 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2005 | 3700 | 0.030 |
Why?
|
| Myopia, Degenerative | 1 | 2015 | 10 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 153 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 1999 | 8592 | 0.030 |
Why?
|
| Retirement | 1 | 2015 | 19 | 0.030 |
Why?
|
| Tissue Donors | 1 | 1998 | 526 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 1996 | 337 | 0.030 |
Why?
|
| Learning | 1 | 1998 | 375 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 814 | 0.030 |
Why?
|
| Reference Values | 1 | 1995 | 742 | 0.030 |
Why?
|
| Vitreous Body | 2 | 1992 | 107 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3741 | 0.030 |
Why?
|
| Antigens, CD | 1 | 1996 | 452 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 866 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1994 | 261 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2013 | 145 | 0.030 |
Why?
|
| Chondroitin Sulfates | 1 | 1993 | 15 | 0.030 |
Why?
|
| Ultrasonic Therapy | 1 | 1993 | 30 | 0.030 |
Why?
|
| Steel | 1 | 1992 | 2 | 0.020 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 1992 | 16 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1996 | 1761 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 1996 | 447 | 0.020 |
Why?
|
| Connective Tissue Diseases | 1 | 1992 | 33 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1993 | 282 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 153 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1992 | 92 | 0.020 |
Why?
|
| Lighting | 1 | 1991 | 19 | 0.020 |
Why?
|
| Electron Probe Microanalysis | 1 | 1991 | 3 | 0.020 |
Why?
|
| Surface Tension | 1 | 1991 | 6 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2011 | 20 | 0.020 |
Why?
|
| Symbolism | 1 | 2011 | 4 | 0.020 |
Why?
|
| Oculomotor Muscles | 1 | 1992 | 75 | 0.020 |
Why?
|
| Eye Abnormalities | 1 | 1992 | 105 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1991 | 85 | 0.020 |
Why?
|
| Gentamicins | 2 | 1989 | 96 | 0.020 |
Why?
|
| Solutions | 1 | 1990 | 66 | 0.020 |
Why?
|
| Rotation | 1 | 2010 | 53 | 0.020 |
Why?
|
| Fluorocarbons | 1 | 1991 | 59 | 0.020 |
Why?
|
| Risk Factors | 3 | 2006 | 11103 | 0.020 |
Why?
|
| Neodymium | 1 | 1990 | 6 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 1991 | 235 | 0.020 |
Why?
|
| Polypropylenes | 1 | 1990 | 16 | 0.020 |
Why?
|
| Haplotypes | 1 | 1992 | 562 | 0.020 |
Why?
|
| Epithelium | 2 | 1997 | 370 | 0.020 |
Why?
|
| Causality | 1 | 1990 | 94 | 0.020 |
Why?
|
| Computer Graphics | 1 | 1989 | 39 | 0.020 |
Why?
|
| Random Allocation | 1 | 1990 | 449 | 0.020 |
Why?
|
| Calibration | 1 | 1989 | 100 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 1989 | 20 | 0.020 |
Why?
|
| Microchemistry | 1 | 1988 | 7 | 0.020 |
Why?
|
| Uveal Diseases | 1 | 1988 | 2 | 0.020 |
Why?
|
| Hemiplegia | 1 | 1989 | 46 | 0.020 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1989 | 57 | 0.020 |
Why?
|
| Hematocrit | 1 | 1988 | 116 | 0.020 |
Why?
|
| Propionibacterium acnes | 1 | 1988 | 13 | 0.020 |
Why?
|
| Cefazolin | 1 | 1988 | 21 | 0.020 |
Why?
|
| Endothelium | 2 | 1988 | 71 | 0.020 |
Why?
|
| Administration, Topical | 1 | 1988 | 144 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1988 | 254 | 0.020 |
Why?
|
| Abscess | 1 | 1989 | 141 | 0.020 |
Why?
|
| Prednisone | 1 | 1988 | 289 | 0.020 |
Why?
|
| Fluorophotometry | 1 | 2006 | 30 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1988 | 729 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 1989 | 983 | 0.010 |
Why?
|
| Oxygen | 1 | 1988 | 577 | 0.010 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2004 | 17 | 0.010 |
Why?
|
| Age Factors | 1 | 1991 | 2985 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2003 | 364 | 0.010 |
Why?
|
| Device Removal | 1 | 2001 | 225 | 0.010 |
Why?
|
| Premedication | 1 | 1997 | 42 | 0.010 |
Why?
|
| Weightlessness | 1 | 1999 | 79 | 0.010 |
Why?
|
| Corneal Edema | 1 | 1997 | 14 | 0.010 |
Why?
|
| Blepharitis | 1 | 1997 | 8 | 0.010 |
Why?
|
| Nonprescription Drugs | 1 | 1997 | 51 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 1997 | 102 | 0.010 |
Why?
|
| Viscosity | 1 | 1996 | 43 | 0.010 |
Why?
|
| Macular Edema | 2 | 1988 | 99 | 0.010 |
Why?
|
| Eyelids | 1 | 1997 | 119 | 0.010 |
Why?
|
| Cicatrix | 1 | 1997 | 129 | 0.010 |
Why?
|
| Cell Division | 1 | 1997 | 774 | 0.010 |
Why?
|
| Conjunctiva | 1 | 1997 | 199 | 0.010 |
Why?
|
| Drainage | 1 | 1996 | 265 | 0.010 |
Why?
|
| Methylmethacrylate | 1 | 1993 | 4 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1997 | 1660 | 0.010 |
Why?
|
| Acute Disease | 1 | 1997 | 1191 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1997 | 1254 | 0.010 |
Why?
|
| Cefoperazone | 1 | 1989 | 1 | 0.000 |
Why?
|
| Panophthalmitis | 1 | 1989 | 2 | 0.000 |
Why?
|
| Uveitis, Anterior | 1 | 1989 | 5 | 0.000 |
Why?
|
| Erwinia | 1 | 1989 | 6 | 0.000 |
Why?
|
| Iritis | 1 | 1988 | 2 | 0.000 |
Why?
|
| Hemorrhoids | 1 | 1989 | 11 | 0.000 |
Why?
|